How do resilient supply chains and procurement policies affect access to medicines in low-resource settings?

• A. Increases bureaucratic delays
• B. Reduces stockouts, ensures quality, timely procurement; policies include buffer stocks, supplier diversity, accountability
• C. Has no effect on access
• D. Always increases costs with no benefit

Answer: (B)

Resilient supply chains and procurement policies improve access to medicines in low-resource settings by preventing stockouts, ensuring medicine quality, and enabling timely delivery. When stockouts occur, patients lose trust in the health system and may delay or forgo treatment; buffer stocks at facilities and warehouses create a cushion against funding gaps, demand surges, and transportation disruptions, so medicines remain available. Diversifying suppliers reduces dependence on a single vendor, so a disruption with one supplier doesn’t halt access. Streamlined, transparent procurement processes shorten lead times, improve ordering accuracy, and ensure that funds translate into actual medicines reaching facilities before they expire. Strong accountability and clear performance monitoring reduce waste, corruption, and inefficiencies, helping ensure that resources are used to obtain and distribute medicines effectively. Quality assurance mechanisms, such as supplier qualification and ongoing quality checks, protect patients from substandard or counterfeit products, which is crucial for trust and continued use of essential medicines. While establishing these systems may require upfront investment and coordination, they typically lower overall costs by reducing stockouts, waste, and delays, and by improving health outcomes.